Biomed. Papers 148(1), 69-73 (2004) | DOI: 10.5507/bp.2004.012

TELMISARTAN IN THE TREATMENT OF HYPERTENSION IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY

Otilie Weinbergová^a, Rudolf Metelka^b, Jiří Vymětal^b, Karel Konečný^b, Zdena Kosatíková^b

^a Faculty of Medicine, Palacky University, Olomouc, Czech Republic

^b 3rd Clinic of Internal Medicine, Teaching Hospital, Olomouc

The primary aim of this study was evaluation of the efficacy of telmisartan (angiotensin II receptor blocker- AT₁ blocker) on blood pressure in 10 patients with renal impairment in moderate or advanced stages of renal insufficiency and not dependent on haemodialysis. Its effect on proteinuria, renal function (represented by serum urea, creatinine, glomerular filtration), evaluation of overall therapy compliance in comparison with a previously prescribed angiotensin converting enzyme inhibitors (ACEI) were secondary aims. Considering the presence of left ventricle hypertrophy in all patients as a marker of hypertensive cardiopathy, the effect of telmisartan therapy on non-invasive cardiovascular parameters (ECG, echocardiography, and assessment of heart rate variability-HRV) was also evaluated. The study group involved 10 hypertensive patients (6 women, 4 men) with diabetic and non-diabetic renal impairment, proteinuria above 1 g/24 hours, hypertensive cardiopathy and intolerance of ACEI (cough). Telmisartan was added to their long-term antihypertensive combination therapy in a dose of 40 mg for the first 14 days, after which the dose increased to the maximal of 80 mg. The average initial daytime systolic blood pressure (SBP) was 149 ± 19.7 mm Hg, average night-time SBP 145 ± 23.0 mm Hg, average initial daytime diastolic BP (DBP) 90.6 ± 2.5 mm Hg, night-time DBP 88.9 ± 13.5 mm Hg. Average initial serum creatinine was 207.2 ± 48.5 µmol/l, urea 15.1 ± 4.4 mmol/l, GF 0.5 ± 0.1 ml/s. Echocardiography revealed left ventricular (LV) hypertrophy with well preserved systolic and moderately impaired diastolic LV function. Also the HRV assessment revealed impaired neurovegetative (e.g. sympathovagal) balance. After 1 year of combination therapy with telmisartan, there was a clearly significant reduction in both SBP and DBP in both day and night-time (SBP daytime 149.6 vs.116.6 mm Hg, night-time 145.8 vs. 129.5 mm Hg; DBP daytime 90.6 vs. 83.5 mm Hg, night-time 88.9 vs. 79,3 mm Hg) and proteinuria (2.37 vs. 1.27 g/24 hour, p < 0.05). There were no signifi cant changes in serum creatinine, urea values, and LV functions. On the other hand, further progression of the sympathovagal balance impairment was noted (continuing reduction of HRV in 9 from 10 patients), which can be described as the priority finding. The total compliance of telmisartan therapy was very good and without adverse clinical side effects. In conclusion - telmisartan reduces blood pressure and proteinuria safely and effectively in patients with various types of nephropathy in moderate or advanced stages of renal insufficiency.

Keywords: Renal insuffi ciency, Proteinuria, Antihypertensive therapy, Angiotensin II receptor blockers, AT1 blockers, Heart

Received: March 15, 2004; Accepted: May 19, 2004; Published: July 1, 2004  Show citation